LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced the release of an abstract on its drug candidate PB272
(neratinib) that will be presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting, which will be held June 3–7, 2016, in
Chicago. Abstracts are available to the public online on the ASCO
website: www.abstract.asco.org.
Abstract #516: Phase II Trial of Neratinib for HER2
Mutated, Non-Amplified Metastatic Breast Cancer (HER2mut
MBC)
Poster Session: Breast Cancer-HER2/ER; Sunday, June 5, 8:00–11:30 a.m.
CDT, Hall A, Poster Board #4
The abstract will be included in the Poster Discussion Session: Breast
Cancer—HER2/ER; Sunday, June 5, 11:30 a.m.–12:45 p.m. CDT, June 5, Hall
D2
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on
the development and commercialization of innovative products to enhance
cancer care. The Company in-licenses the global development and
commercialization rights to three drug candidates—PB272 (neratinib
(oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a
potent irreversible tyrosine kinase inhibitor that blocks signal
transduction through the epidermal growth factor receptors, HER1, HER2
and HER4. Currently, the Company is primarily focused on the development
of the oral version of neratinib, and its most advanced drug candidates
are directed at the treatment of HER2-positive breast cancer. The
Company believes that neratinib has clinical application in the
treatment of several other cancers as well, including non-small cell
lung cancer and other tumor types that over-express or have a mutation
in HER2.
Further information about Puma Biotechnology can be found at www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and actual
outcomes and results could differ materially from these statements due
to a number of factors, which include, but are not limited to, the risk
factors disclosed in the periodic reports filed by the Company with the
Securities and Exchange Commission from time to time. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company assumes
no obligation to update these forward-looking statements, except as
required by law.
Contact: